GlobeNewswire Inc | Jan 8, 2021 04:05PM EST

January 08, 2021

BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenexs CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenexs senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously scheduled presentation time, and investor one-on-one meetings.

AboutAthenex, Inc.

Founded in 2003,Athenex, Inc.is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer.Athenexis organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Companys current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenexs employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenexhas offices inBuffaloandClarence, New York;Cranford, New Jersey;Houston, Texas;Chicago, Illinois;Hong Kong;Taipei,Taiwan; multiple locations inChongqing, China;Manchester, UK;Guatemala City,GuatemalaandBuenos Aires, Argentina. For more information, please visitwww.athenex.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as anticipate, believe, continue, could, estimate, expect, foresee, goal, guidance, intend, likely, may, plan, potential, predict, preliminary, probable, project, promising, seek, should, will, would, and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenexs business; our history of operating losses and need to raise additional capital to continue as a going concern; uncertainties around our ability to meet funding conditions under our financing agreements and access to capital thereunder; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; competition; intellectual property risks; risks relating to doing business internationally and inChina; the risk of production slowdowns or stoppages or other interruptions at ourChongqingfacilities; and the other risk factors set forth from time to time in ourSECfilings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-secor upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTS

Investors

Steve RubisAthenex, Inc.Email:stevenrubis@athenex.com

Daniel Lang, MDAthenex, Inc.Email:danlang@athenex.com

Tim McCarthyLifeSci Advisors, LLCEmail:tim@lifesciadvisors.com